Across TCGA pan-cancer cohorts, FOXD4L1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FOXD4L1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FOXD4L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FOXD4L1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, DLBC, and STAD are the cancer types where FOXD4L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.051	0.712	<.001	24	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
STAD	DFS	Median	All	1.000	0.390	.038	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FOXD4L1 tumor-vs-normal RNA expression · all FOXD4L1 data types